Method for safety evaluation of chemical compound using recombinant yeast expressing human cytochrome P450

Abstract: There is disclosed a method for evaluation of the safety of a chemical compound, which includes the steps of: (a) reacting a chemical compound with recombinant yeast cells expressing, or in other words producing, human cytochrome P450 molecular species P450 1A2, P450 2C9, P450 2E1 and P450 3A4 together with a yeast NADPH-P450 reductase, which may be in the form of a fused enzyme with each of said human cytochrome P450 molecular species, or with the cell free extracts of the yeast cells; and (b) analyzing the resulting metabolite to determine the safety of the compound. According to this method, it can be determined whether a test compound will be converted into a carcinogenic or mutagenic form through the metabolism in the human liver, and whether the test compound or its metabolite has mutagenicity.

Description: The present invention relates to a method for evaluation of the safety of a chemical compound using recombinant yeasts expressing human cytochrome P450. The cytochrome P450 is an enzyme catalyzing the mono-oxygenation of a substance in the human liver. In the past there have been several approaches to combine the monoxygenase activity of a cytochrome P450 with the reducing power supplying ability derived from NADPH-cytochrome P450. WO-A-9 308 260 discloses a method for degrading complex chemical mixtures such as crude oils by using at least one eukaryotic (including mammalian) P450 expressed in yeast cells. Further, this publication generally reviews a number of prior art documents relating to the construction of enzymes and expression methods. US-A-5 111 852 discloses the production of a fused enzyme from rat liver CYP1A1 and rat reductase. JP-A-02 249 488 and JP-A-02 023 870 specifically disclose the production of a fused enzyme from bovine adrenal cytochrome P450c21 and yeast NADPH-P450 reductase. However, there is no disclosure of a fused enzyme from a human liver P450. It is known that recombinant human cells expressing heterogeneous human cytochrome P450 species have been used for the determination of metabolisms and toxicities of chemical substances. However, this method is unsatisfactory as a method of evaluation of the safety of chemical compounds partly because the kinds of the human cytochrome P450 species expressed by the cells and the levels of the expression are so limited that the amount of metabolite obtained is not enough for determination of the metabolism and toxicity, and partly because it requires not only a high density culture technique but a high cultivation cost. Accordingly, there has been a great demand for developing an advantageous method. As a result of the extensive study, the present inventors have found that yeasts are particularly suitable as hosts for production of human cytochrome P450 and yeast NADPH-P450 reductase to be used in in vitro determination of metabolisms and toxicities of chemical substances because yeasts grow so rapidly and can stably express both the human cytochrome P450 and yeast NADPH-P450 reductase at high expression levels to provide sufficient amounts of the metabolites in a short period of time, thereby enabling a precise and quick analysis of the metabolites. Moreover, they have also found that, despite that there are a considerable number of human cytochrome P450 molecular species, the human metabolic system for chemical compounds can be reproduced in vitro when at least four human cytochrome P450 molecular species, i.e., human cytochrome P450 1A2, P450 2C9, P450 2E1 and P450 3A4, are combined. Thus, the present invention provides a method for evaluation of the safety of a chemical compound, which comprises the steps of: (a) reacting a chemical compound with recombinant yeast cells expressing, or in other words producing, human cytochrome P450 molecular species P450 1A2, P450 2C9, P450 2E1 and P450 3A4 together with a yeast NADPH-P450 reductase, which may be in the form of a fused enzyme with each of said human cytochrome P450 molecular species, or with the cell free extracts of the yeast cells; and (b) analyzing the resulting metabolite to determine the safety of the compound. The present invention further provides a method for determination of the human metabolite of a chemical compound, which comprises the steps of: (a) reacting a chemical compound with recombinant yeast cells producing human cytochrome P450 molecular species P450 1A2, P450 2C9, P450 2E1 and P450 3A4 together with a yeast NADPH-P450 reductase, which may be in the form of a fused enzyme with each of said human cytochrome P450 molecular species, or with cell free extracts of the yeast cells; and (b) identifying the resulting metabolite. Figs. 1 to 4 show various primers for cloning human P450 genes. Fig. 5 shows a synthetic linker for human P450 gene cloning. Fig. 6 shows a method of constructing yeast expression plasmids for human P450 1A2. Fig. 7 shows a method of constructing yeast expression plasmids for human P450 2C9. Fig. 8 shows a method of constructing yeast expression plasmids for human P450 2E1. Fig. 9 shows a method of constructing yeast expression plasmids for human P450 3A4. Fig. 10 shows a method of constructing yeast expression plasmids for human P450 1A1. Fig. 11 shows a method of constructing yeast expression plasmids for human P450 2A6. Fig. 12 shows a method of constructing yeast expression plasmids for human P450 2B6. Fig. 13 shows a method of constructing yeast expression plasmids for human P450 2C8. Fig. 14 shows a method of constructing yeast expression plasmids for human P450 2C18. Fig. 15 shows a method of constructing yeast expression plasmids for human P450 2C19. Fig. 16 shows a method of constructing yeast expression plasmids for human P450 2D6. Fig. 17 shows a method of constructing a yeast expression plasmid containing an artificial fused enzyme gene. Fig. 18 shows a method of constructing a yeast expression plasmid using a GAPDH promoter. According to the present invention, it can be determined whether a test compound will be converted into a carcinogenic or mutagenic form through the metabolism in the human liver, and whether the test compound or its metabolite has mutagenicity. Thus, the present invention provides a method for evaluation of safety of a chemical compound, and a method for determination of the human metabolite of a chemical compound. Human Cytochromes P450 and Their Genes The yeasts capable of expressing, or producing, said enzymes can be obtained by transforming them with expression plasmids containing genes encoding said enzymes with a conventional recombinant DNA method. The human P450 molecular species to be used in the present invention include at least four human cytochrome P450 molecular species, i.e., human cytochrome P450 1A2, P450 2C9, P450 2E1 and P450 3A4. The genes encoding these essential human cytochrome P450 molecular species and yeast NADPH-P450 reductase are reported in Nucleic Acids Res., 14, 6773-6774, 1986; J. Biochem., 102, 1075-1082, 1987; J. Biol. Chem., 261, 16689-16697, 1986; DNA, 7, 79-86, 1988; and J. Biochem., 103, 1004-1010, 1988. Although the kinds of P450 molecular species present in human liver vary among the race and individuals, the combination of said human P450 molecular species includes at least about 85% (molar ratio) of the total amount of the human P450 molecular species present in the human liver. Hence, the present method using the said combination of human P450 molecular species can accurately reproduce the human liver metabolism in vitro. The combination of these P450 molecular species may optionally be varied, taking into account of the amounts of these P450 molecular species in the liver: the amount of P450 3A4 present in the human liver is about 35±10% of the total amount of the human P450 molecular species; P450 2C9 about 25±10%; P450 1A2 about 23±10%; and P450 2E1 about 17±10%. In addition to the above-mentioned combination, human P450 molecular species P450 2A6, P450 2C19 and/or P450 2D6 (Biochemistry, 29, 1322-1329, 1990; Biochemistry, 30, 3247-3255, 1991; Am. J. Hum. Genet., 45, 889-904, 1989) may also be added. In this case, the combined human P450 molecular species covers at least 90% of the total amount of the human P450 molecular species present in the human liver. The in vitro human metabolic system that reproduces accurately the human metabolism of a chemical compound, and can represent the differences among races and individuals can be obtained when these human P450 molecular species are properly combined, taking into account of the amounts of these species in the liver. Furthermore, at least one human cytochrome P450 molecular species selected from the group of P450 1A1, P450 2B6, P450 2C8 and P450 2C18 (Science, 228, 80-83, 1985; Biochemistry, 28, 7340-7348, 1989; Nucleic Acids Res., 15, 10053-10054, 1987; Biochemistry, 30, 3247-3255, 1991) may be added to said human cytochrome P450 molecular species to reproduce in vitro the metabolism of the human liver more accurately. The nucleotide sequences coding for the human P450 molecular species are disclosed in SEQ ID NOs: 1 to 38. Cloning of Genes The genes coding for the human cytochrome P450 molecular species are known and can be obtained by the conventional cloning methods. For example, they may be obtained by: (i) preparing a mRNA fraction containing the mRNA of the gene coding for human cytochrome P450 molecular species; (ii) preparing a cDNA from the mRNA fraction using reverse transcriptase; (iii) preparing a cDNA library by inserting said cDNA into a pharge vector or a plasmid vector; and (iv) cloning the gene coding for the human cytochrome P450 molecular species from the cDNA library obtained above or from a commercially available human liver-derived cDNA library using a DNA fragment having an identical sequence to some part of the desired gene or an antibody reactive to the protein encoded by the gene. The gene may also be obtained from the above-described cDNA library by the PCR method. The gene coding for yeast NADPH-P450 reductase may be obtained by the same method as used for cloning of the genes coding for human P450 molecular species. More specifically, the gene may be obtained by such a known method as described in the Japanese Patent Laid-open Publication No. 62-19085. Construction of Yeast Expression Plasmids The yeasts capable of expressing said enzymes can be obtained by transforming them with expression plasmids containing genes encoding said enzymes with a conventional recombinant DNA method. The yeast expression plasmid having a gene coding for human P450 molecular species and a gene coding for the yeast NADPH-P450 reductase can be constructed by using a conventional recombinant DNA method. As to the promoter to be used for construction of the expression plasmids for the yeast of the present invention, there is no particular restriction so long as the promoter can be used in usual expression systems for yeasts, and a promoter of a yeast alcohol dehydrogenase gene (herein-after referred to as ADH promoter), glyceraldehyde-3-phosphate dehydrogenase promoter (hereinafter referred to as GAPDH promoter), and phosphoglycerate kinase Promoter (hereinafter referred to as PGK promoter) are preferably used in the present invention. The ADH promoter can be prepared by a usual genetic engineering method, for example, from a yeast expression vector pAAH5 possessing a yeast ADH1 promoter and terminator ("Methods in Enzymology" by Ammerer et al., vol.101, pp.192-201). The yeast ADH1 promoter is described in the U.S. Patent Application No. 299,733 of Washington Research Foundation and, if granted, will require patent license from the patentee in a case of using the same for an industrial or commercial purpose. The yeast expression plasmid having both a gene coding for human P450 molecular species and a gene coding for the yeast NADPH-P450 reductase can be constructed by, for example, inserting an NotI fragment prepared from yeast expression vector pAAH5N possessing the ADH promoter and terminator (Japanese Patent Laid-open Publication No. 2-211880) to an NotI site of plasmid pARRN possessing a gene coding for yeast NADPH-P450 reductase (Japanese Patent Laid-open Publication No. 2-211880) and then inserting cDNA coding for the human P450 molecular species to the HindIII site of the thus obtained plasmid pAHRR. Moreover, a vector obtained by exchanging a Hind III site of pAAH5N with another restriction enzyme site may be used for the same purpose. In the present invention a gene coding for an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase can also be used. The artificial fused enzyme can catalyze mono-oxygenation reaction and the efficiency of the electron transfer from NADPH is so improved that the activity of the mono-oxygenation reaction is much enhanced. Accordingly, a great amount of metabolic products can be obtained in a shorter period of time, enabling accurate analysis. The fused gene comprises a gene coding for the human cytochrome P450 molecule on the 5'-terminus and a gene coding for the yeast NADPH-P450 reductase on 3'-terminus. The gene coding for such an artificial fused enzyme can be constructed by ligating a gene coding for a human cytochrome P450 species and a gene coding for yeast NADPH-P450 reductase by a conventional recombinant DNA method, and the constructed gene is usually inserted to the Hind III site of the yeast expression vector pAAH5N having ADH promoter and ADH terminator described in the Japanese Patent Laid-open Publication No. 2-211880. Transformation of Yeast The yeast cells expressing the human P450 molecular species and yeast NADPH-P450 reductase or yeast cells expressing an artificial fused enzyme comprising human P450 molecular species and NADPH-P450 reductase can be obtained by introducing the thus constructed yeast expression plasmid into a yeast by a known method such as a protoplast method or a method using alkaline metal salt (LiCl). In the present invention, two or more expression plasmids may optionally be introduced into a single strain of yeast so that the yeast can express two or more molecular species simultaneously. As the hosts, Saccharomyces cerevisiae is used in the method of the present invention, in particular, Saccharomyces cerevisiae AH22 (ATCC 38626) is preferably used. Reaction of Test Compound In the method of the present invention, a test compound is reacted with a mixture of at least said four human P450 molecular species, or separately with each of the said four human P450 molecular species in the presence of the yeast NADPH-P450 reductase. Alternatively, it may be first reacted with one or more of the essential human P450 molecular species, and then with a mixture of, or separately with the rest of them; each of the reactions is carried out in the presence of the yeast NADPH-P450 reductase. The reaction is carried out by reacting a test compound with the yeast obtained by the transformation with an expression plasmid containing a gene encoding a human P450 molecular species and a gene encoding yeast NADPH-P450 reductase, or a fused gene encoding a fused enzyme of a human P450 molecular species and a yeast NADPH-P450 reductase, or with the cell free extracts of the yeast cells. In the reaction of a test compound with the enzymes of the present invention, living yeast cells and their cell free extracts are usually used. As the cell free extracts, subcellular fractions of cells containing microsomal fractions, or fractions containing both microsome and cytoplasm are used. The cell free extracts or fractions can be prepared, for example, by a known method (DNA, Vol.4, No.3, pp.203-210 (1985)). However, the present invention can be preferably carried out with the cell free extracts, especially with microsomal fractions of the cells. But, when biological analytic method is used for the determination of the mutagenicity or carcinogenicity, fractions containing microsome and cytoplasm are preferably used. The reaction can be conducted by adding a test compound to a culture solution or a buffer solution of yeast cells or cell free extracts, and the resultant solution is usually incubated at a temperature, for example, at about 10°C to 40°C, for about 0.1 to 48 hours. The amounts of the yeast cells or cell free extracts and the compound vary depending on the conditions such as reaction temperature, reaction time and the kind of the test compound to be used. For instance, the amount of the yeast cells to be used in the solution is preferably from about 10 5 to about 10 10 per 1 ml of the solution , preferably, from about 10 7 to about 10 8 per 1 ml of the solution. When cell free extracts are used, from about 10 10 to about 10 15 of P450 molecules per 1 ml of the solution, preferably from about 10 12 to about 10 13 of P450 molecules per 1 ml of the solution is usually used. The amount of the compound to be added is preferably within a range of from about 0.01 µmol to about 1µmol per 1 ml of the solution. The above ranges may be optionally varied, if necessary. Determination of Metabolites The metabolites present in the reaction solution can then be subjected to elucidation of the chemical structures and the measurement of their amounts. The analysis of the chemical structure can be conducted by known methods ("Guide to Apparatus Analysis (2)", edited by Jiro Shiokawa et al., (revised edition) first print, issued from Kagaku Dojin (1985); "Spectral Identification for Organic Compound" by R.M. Silverstein, fourth edition, third print, issued from Tokyo Kagaku Dojin (1984)). From the results of the analysis of the metabolites, it can be determined whether the tested compound will be detoxicated or metabolized into a carcinogen in the human liver when administered. Determination of Toxic Effects of Metabolites The toxic effects, in particular mutagenicity, of the resulting metabolites can be determined by a conventional biological analytic method such as the Ames Test. For example, the metabolites present in the reaction solution are allowed to react with mutant bacteria such as histidine requiring Salmonella strain (Salmonella typhimurium (his-)), or tryptophan requiring Escherichia coli (Escherichia coli (trp-)), and then it is determined whether the metabolites cause the back mutation of the bacteria whether the colonies of revertant which is not requiring the amino acid (His+ or Trp+) are formed, and, if formed, how many colonies. In place of the bacteria, mammalian cells such as MCL-5 cells, which are sensitive to cell toxicity of a chemical compound (U.S. Patent No. 4,532,204), can be used. In this method, the compounds that cause the back mutation will be judged to be mutagenicity test-positive. It is also possible to simultaneously proceed the step (a) of reacting the test compound with the yeast cells or the cell free extracts, and the step (b) of analyzing the metabolites present in the reaction solution. The mutagenicity of arylamine derivatives, which are known to be metabolized by the liver into a mutagen, can be examined by the biological analytic method. For example, the mutagenicity of 2-aminoanthrathene can be detected at the concentration of about 0.1 µg of 2-aminoanthrathene when 20 pmol of P450 1A2, which is active specifically to 2-aminoanthrathene, is used (Table 1). In the present invention, a metabolic probe for a human P450 molecular species can be obtained. If a certain chemical compound is converted by a particular human P450 molecular species into a specific metabolite, the amount of such a human P450 molecular species can be determined by detecting such a metabolite in excretions such as blood or urine of a living body who has been administered the compound, and such a compound is called a metabolic probe. In the present invention, such a metabolic probe can be obtained by screening the metabolites obtained by reacting chemical compounds with the yeasts of the present invention. Examples The present invention will be further illustrated by the following examples, which are not to be construed to limit the scope thereof. Preparation of cDNA coding for human P450 molecular species cDNA coding for human P450 molecular species were obtained from a commercially available human liver cDNA library (Clontech Co.) by the PCR method using primers for cloning human P450 genes as shown in Figs. 1 to 4, and a method using a synthetic linker for human P450 gene cloning as shown in Fig. 5. Thus obtained nucleotide sequences for the cDNA and the deduced amino acid sequences are shown in the sequence listing. Relationship between SEQ ID NOs and human P450 molecular species are as follows: 1. The essential human cytochrome P450 molecular species the present invention. (1) SEQ ID NO: 1 1A2 (2) SEQ ID NO: 3 2C9 (3) SEQ ID NO: 5 2E1 (4) SEQ ID NO: 7 3A4. 2. Auxiliary Human cytochrome P450 molecular species (1) SEQ ID NOs: 9, 11 and 13 1A1 (2) SEQ ID NOs: 15 and 17 2A6 (3) SEQ ID NO: 19 2B6 (4) SEQ ID NOs: 21, 23 and 25 2C8 (5) SEQ ID NO: 27 2C18 (6) SEQ ID NO: 29 2C19 (7) SEQ ID NOs: 31, 33, 35 and 37 2D6 Construction of yeast expression plasmids: p1A2 and p1A2R Fig. 6 shows a method of constructing yeast expression plasmids for human P450 1A2. The protein coding region of P450 1A2 gene of about 1.5 kb excluding about 40 bp at the 5'-terminal was amplified by the PCR method using the primers shown in Fig. 1. The resultant fragment of about 1.5 kb was cleaved with SacI and sub-cloned to a pUC118 vector. About 40 bp at the 5'-terminal was chemically synthesized as the linkers shown in Fig. 5 and sub-cloned between the HindIII and SacI sites of the pUC118 vector. The plasmid having the 1.5 kb fragment was digested by HindIII, blunted, and then ligated with an EcoRI linker. The EcoRI-SacI fragment was prepared from the resulting plasmid and ligated into the plasmid containing the 5'-terminal 40 bp. Then, it was treated with EcoRI and blunted. A HindIII linker was inserted into the blunted fragment. The obtained fragment then cleaved with HindIII was inserted into pAAH5N and pAHRR to construct a yeast expression plasmid p1A2 for human P450 1A2, and a yeast expression plasmid p1A2R for simultaneous expression of human P450 1A2 and yeast NADPH-P450 reductase. Construction of yeast expression plasmids: p2C9 and p2C9R Fig. 7 shows a method of constructing yeast expression plasmids for human P450 2C9. The protein coding region of P450 2C9 gene was divided into two fragments of about 0.9 kb and about 0.6 kb, and the fragments were amplified by the PCR method using the primers shown in Fig. 1. The resultant fragment of about 0.9 kb was cleaved with PstI and sub-cloned to a pUC B vector, which was prepared by exchanging the cloning site located between the two Hind III sites, one of which was obtained by converting the EcoRI site of pUC19, with the following cloning sites: The fragment of about 0.6 kb was incorporated between the XbaI and PstI sites of the plasmid having the 0.9 kb fragment to ligate the two segments. The KpnI site of the plasmid was blunted. An XbaI linker was inserted to the blunted plasmid. The XbaI fragment containing the coding region was cut out from the resultant fragment. A modified pUC vector, pUCAN, was constructed by replacing the EcoRI and HindIII sites with NotI sites, followed by insertion of the NotI fragment prepared from pAAH5N between the two NotI sites. The HindIII site of pUCAN vector having the ADH promoter and terminator regions in the pUC vector was blunted and inserted into pUCANX introduced with the XbaI linker. The obtained plasmid was cleaved with NotI and inserted into pAAH5N and pAHRR treated in a similar manner with NotI to construct a yeast expression plasmid p2C9 for human P450 2C9, and a yeast expression plasmid p2C9R for simultaneous expression of human P450 2C9 and yeast NADPH-P450 reductase. Construction of yeast expression plasmids: p2E1 and p2E1R Fig. 8 shows a method of constructing yeast expression plasmids for human P450 2E1. The protein coding region of P450 2E1 gene was divided into two fragments of about 0.5 kb and about 1.0 kb, both of which were amplified by the PCR method using the primers shown in Fig. 1. The resultant fragment of about 0.5 kb was cleaved with EcoRI and BamHI and sub-cloned to a pUC118 vector. Then the fragment of about 1.0 kb was incorporated between the BamHI and SphI sites to ligate the two fragments. This was cleaved with EcoRI, and SphI, and inserted into pUC B first and then cut out with HindIII. The resultant fragment was inserted into the pAAH5N and pAHRR vectors to construct a yeast expression plasmid p2E1 for human P450 2E1, and a yeast expression plasmid p2E1R for simultaneous expression of human P450 2E1 and yeast NADPH-P450 reductase. Construction of yeast expression plasmids: p3A4 and p3A4R Fig. 9 shows a method of constructing yeast expression plasmids for human P450 3A4. The protein coding region of P450 3A4 gene was divided into two fragments of about 0.6 kb and about 0.9 kb, both of which were amplified by the PCR method using the primers shown in Fig. 2. The resultant fragment of about 0.6 kb was cleaved with SacI and sub-cloned to a pUC118 vector. Subsequently, it was cleaved with EcoRI and blunted. An XbaI linker was ligated to the blunted fragment. The fragment of 0.9 kb was cleaved with XbaI and SacI, and incorporated to the resultant fragment above, thus the two fragments were ligated. After cleaving the plasmid with SphI, it was blunted. An XbaI linker was ligated to the blunted fragment, from which the XbaI segment was cut out and inserted to an XbaI site of pUCANX. This was cut out with NotI and inserted into pAAH5N and pAHRR treated in a similar manner with NotI. Thus a yeast expression plasmid p3A4 for human P450 3A4, and a yeast expression plasmid p3A4R for simultaneous expression of human P450 3A4 and yeast NADPH-P450 reductase were constructed. Construction of yeast expression plasmids: p1A1 and p1A1R Fig. 10 shows a method of constructing yeast expression plasmids for human P450 1A1. The coding region for P450 1A1 protein was divided into two fragments of about 1.0 kb and about 0.5 kb and the resultant fragments were amplified by the PCR method using the primers shown in Fig. 2. Thus obtained fragment of about 1.0 kb was cleaved with XbaI and SacI and sub-cloned to a pUCA vector, which was prepared by exchanging the cloning site located between the two HindIII sites, one of which was obtained by converting the EcoRI site of pUC19, with the following cloning sites: The amplified fragment of about 0.5 kb was sub-cloned into the HincII site of a pUC 19 vector and the resultant plasmid was then cleaved with SacI. The cleaved fragment was ligated with the plasmid having the 1.0 kb fragment. After cutting out the coding region from the thus obtained 1A1 gene with HindIII, the fragment was inserted to the HindIII site of the yeast expression vector pAAH5N having ADH promoter and terminator regions, and to the same site of vector pAHRR for simultaneous expression of P450 and yeast NADPH-P450 reductase of which gene is located upstream of the P450 gene. Thus yeast expression plasmid p1A1 for human P450 1A1 and yeast expression plasmid p1A1R for simultaneous expression of human P450 1A1 and yeast NADPH-P450 reductase were constructed. In addition two kinds of human P450 1A1 gene fragments which were different only in a small portion of the nucleotide sequence were obtained in a similar manner and used to construct two kinds of yeast expression plasmid for human P450 1A1, p1A1 Variant 1 and p1A1 Variant 2, and two kinds of plasmids for simultaneous expression of human P450 1A1 and yeast NADPH-P450 reductase, p1A1R Variant 1 and p1A1R Variant 2. Construction of yeast expression plasmids: p2A6 and p2A6R Fig. 11 shows a method of constructing yeast expression plasmids for human P450 2A6. A protein coding region of P450 2A6 gene was divided into two fragments of about 0.6 kb and about 0.9 kb, both of which were amplified by the PCR method using the primers shown in Fig. 2 to yield two kinds of human P450 2A6 gene fragments which were different only in a small portion of the nucleotide sequence. The resultant fragment of about 0.6 kb was cleaved with XbaI and HincII, and sub-cloned to a pUC A vector. Then the fragment of 0.9 kb was incorporated between the HincII and KpnI sites to ligate the two fragments. The obtained fragment was cleaved with HindIII and inserted into pAAH5N and pAHRR to construct two kinds of yeast expression plasmids for human P450 2A6, p2A6 and p2A6 Variant 1, and two kinds of yeast expression plasmids for simultaneous expression of human P450 2A6 and yeast NADPH-P450 reductase, p2A6R and p2A6R Variant 1. Construction of yeast expression plasmids: p2B6 and p2B6R - Fig. 12 shows a method of constructing yeast expression plasmids for human P450 2B6. The entire protein coding region of P450 2B6 gene was amplified by the PCR method using the primers shown in Fig. 3. The resultant fragment was cleaved with XbaI and BamHI and sub-cloned to pUC A. The resulting plasmid was partially digested with HindIII, and inserted into pAAH5N and pAHRR vectors to construct a yeast expression plasmid p2B6 for human P450 2B6, and a yeast expression plasmid p2B6R for simultaneous expression of human P450 2B6 and yeast NADPH-P450 reductase. Construction of yeast expression plasmids: p2C8 and p2C8R Fig. 13 shows a method of constructing yeast expressed plasmids for human P450 2C8. The entire protein coding region of the P450 2C8 gene was amplified by the PCR method using the primers shown in Fig. 3 to yield three kinds of P450 2C8 genes which were different only in a small portion of the nucleotide sequence. The resultant fragments were partially digested with XbaI, and sub-cloned to pUC A. The fragment was cleaved with HindIII and inserted into pAAH5N and pAHRR vectors to construct three kinds of yeast expression plasmids p2C8, p2C8 Variant 1 and p2C8 Variant 2 for human P450 2C8, and three kinds of yeast expression plasmids, p2C8R, p2C8R Variant 1 and p2C8R Variant 2 for simultaneous expression of human P450 2C8 and yeast NADPH-P450 reductase. Construction of yeast expression plasmids: p2C18 and p2C18R Fig. 14 shows a method of constructing yeast expression plasmids for human P450 2C18. The protein coding region of P450 2C18 gene was divided into two segment of about 1.4 kb and about 0.9 kb, then the both fragments were amplified by the PCR method using the primers shown in Fig. 3. The amplified fragment of about 1.4 kb was cleaved with PstI and sub-cloned to a pUC A vector. The fragment of about 0.9 kb was incorporated between the XbaI and PstI sites to ligate the two fragments. After cleaving the plasmid with SmaI, an XbaI linker was introduced. Then an XbaI fragment was prepared and inserted into the XbaI site of pUCANX. It was cleaved with NotI and inserted into pAAH5N and pAHRR treated in a similar manner with NotI to construct a yeast expression plasmid p2C18 for human P450 2C18, and a yeast expression plasmid p2C18R for simultaneous expression of human P450 2C18 yeast and NADPH-P4-50 reductase. Construction of yeast expression plasmids: p2C19 and p2C19R Fig. 15 shows a method of constructing yeast expression plasmids for human P450 2C19. Fragments a, b and c for the protein coding region of P450 2C19 gene were amplified by the PCR method using the primers No. 1, No. 2, No. 3 and No. 4, No.5 and No.6, and No.5 and No.7 defined by SEQ ID NOs: 39-45, respectively. Fragments e and f for the protein coding region of human cytochrome P450 2C19 were also amplified against human cytochrome P450 2C9 gene by the PCR method using the primers No. 8 to 21 having nucleotide sequences with some mutations shown by SEQ ID NOs: 46 to 59. A fragment d for the linker Nos. 1 and 2 having nucleotide sequences shown by SEQ ID NOs: 60 and 61 was obtained by directly synthesizing the DNA to cover the rest of the protein coding region of the human P450 2C19 gene. Thus the fragments covering the whole protein coding region of the human cytochrome P450 2C19 were obtained. After the fragments a and b were treated with XhoI and BamHI, and with BamHI and PstI, both fragments were simultaneously inserted between the XhoI and PstI sites of the Blue Script(+) vector. The fragment e was treated with XbaI and XhoI and inserted to the XbaI and XhoI sites of the plasmid having the fragments a and b to give a plasmid having the fragments a, b and e. After the fragment c was treated with PstI and KpnI, the resulting fragment was simultaneously inserted with the linker fragment d between the PstI and EcoRI sites of the Blue Script(+). The resultant plasmid was cut with PstI and EcoRI to give a fragment containing the fragments c and d. Then this fragment was simultaneously inserted with the fragment f treated with EcoRI in to the PstI and HincII sites of the aforementioned plasmid containing the fragment a, b and e. Thus a plasmid having the whole coding region of the human cytochrome P450 2C19 gene was constructed. The constructed plasmid was cut with HindIII and the resultant fragment was inserted to pAAH5N and pAHRR both of which were treated with HindIII to give a yeast expression plasmid p2C19 for expressing the human P450 2C19 and a yeast expression plasmid p2C19R for simultaneous expression of the human P450 2C19 and yeast NADPH-P450 reductase. SEQ ID NOs and primer Nos. are as follows: SEQ ID No: 39 Primer No. 1 SEQ ID NO: 40 Primer No. 2 SEQ ID NO: 41 Primer No. 5 SEQ ID NO: 42 Primer No. 4 SEQ ID NO: 43 Primer No. 5 SEQ ID NO: 44 Primer No. 6 SEQ ID NO: 45 Primer No. 7 SEQ ID NO: 46 Primer No. 8 SEQ ID NO: 47 Primer No. 9 SEQ ID NO: 48 Primer No. 10 SEQ ID NO: 49 Primer No. 11 SEQ ID NO: 50 Primer No. 12 SEQ ID NO: 51 Primer No. 13 SEQ ID NO: 52 Primer No. 14 SEQ ID NO: 53 Primer No. 15 SEQ ID NO: 54 Primer No. 16 SEQ ID NO: 55 Primer No. 17 SEQ ID NO: 56 Primer No. 18 SEQ ID NO: 57 Primer No. 19 SEQ ID NO: 58 Primer No. 20 SEQ ID NO: 59 Primer No. 21 SEQ ID NO: 60 Linker No. 1 SEQ ID NO: 61 Linker No. 2 Construction of yeast expression plasmids: p2D6 and p2D6R Fig. 16 shows a method of constructing yeast expression plasmids for human P450 2D6. The protein coding region of 1.3 kb excluding about 200 bp at the 5'-terminal of P450 2D6 gene was divided into two fragments of about 0.4 kb and about 0.9 kb, and the both fragments were amplified by the PCR method. The resultant fragment of about 0.9 kb was cleaved with KpnI and sub-cloned to pUC A. For the 200 bp on the 5'-terminal, three synthetic linkers shown in Fig. 5 were used and two linkers on the 5'-terminal were incorporated into XbaI and PstI sites of a Blue Script(+) vector and then other linkers were incorporated into SmaI and PstI sites. Then the fragment of about 0.4 kb obtained by the PCR method was incorporated into the PstI and HincII sites of the plasmid and then cleaved with NspV and XbaI. The resultant fragment was inserted into the plasmid containing the 0.9 kb fragment to ligate the coding region. This was cleaved with HindIII and inserted into pAAH5N and pAHRR vectors to construct a yeast expression plasmid p2D6 for human P450 2D6, and a yeast expression plasmid p2D6R for simultaneous expression of human P450 2D6 and yeast NADPH-P450 reductase. Then three kinds of human P450 2D6 gene fragments which were different only in a small portion of the nucleotide sequence were obtained in a similar manner as described above and used to construct two kinds of yeast expression plasmids for human P450 2D6, p2D6 Variant 1, p2D6 Variant 2 and p2D6 Variant 3, and three kinds of yeast expression plasmid 2D6R for simultaneous expression of human P450 2D6 and yeast NADPH-P450 reductase, p2D6R Variant 1, p2D6R Variant 2 and p2D6R Variant 3. Construction of yeast expression plasmid containing artificial fused enzyme gene An expression plasmid was constructed in accordance with Fig. 17. The XbaI-XhoI fragment was amplified with plasmid p3A4 by using the primers shown in Fig. 4. On the other hand, the XhoI-HindIII fragment of about 2.1 kb was obtained from the plasmid pBFCRI (Japanese Patent Application No. 4-209226) and inserted between the XhoI and HindIII sites of a commercial vector Blue Script(+), followed by digestion with restriction enzymes XhoI and XbaI. These two fragments were simultaneously inserted to the XbaI site of the vector pUCAN, which was then digested with NotI to give a fragment of about 5.6 kb. The desired yeast expression plasmid pF3A4 was obtained by ligating the fragment with the NotI fragment of about 10.5 kb obtained from vector pAAH5N (Japanese Patent Laid-open Publication No. 2-211880). The artificial fused enzyme consists of 1156 amino acid residues of which sequence structure comprising, successively, from the N-terminal end, an entire amino acid sequence (503 residues) of human liver cytochrome P450 3A4, a linker-derived sequence (Ala-Arg-Ala), and a sequence from the 42nd residue to C-terminal of yeast NADPH-cytochrome P450 reductase. Preparation of transformed yeast cell Saccharomyces cerevisiae AH 22 was inoculated to 1.0 ml of YPD culture medium (1% yeast extract, 2% polypeptone, 2% glucose). After shaken at 30 °C for 18 hours, the yeast cells were collected by centrifugation (5000 x g, 10 min). The resultant cells were suspended in 10 ml of 0.2 M LiCl solution and then centrifuged again (5000 x g, 10 min) to obtain pellets. Then 20 µl of 1 M LiCl solution, 30 µl of 70% polyethylene glycol 4000 and each 10 µl solution containing about 1.0 µg of various kinds of yeast expression plasmids for the human P450 molecular species and yeast NADPH-reductase constructed as above were added to the resultant pellets. After sufficiently mixing them, they were incubated at 30°C for one hour and further stirred after the addition of 140 µl of sterilized water. The solution was plated on SD synthetic culture medium (2.0% glucose, 0.67% nitrogen base w/o amino acids, manufactured by Difco Co., 20 µg/ml of histidine, 2.0% agar) and incubated at 30 °C for three days. Then transformed yeast cells possessing the yeast expression plasmid described above were selected. In this way, various kinds of yeast cells expressing the human P450 molecular species were prepared. Quantitative measurement of human P450 expressed in yeast Each 200 ml of culture broth of each kind of yeast cells expressing human P450 molecular species and yeast NADPH-reductase simultaneously or expressing an artificial fused enzyme comprising human P450 molecular species and yeast NADPH-reductase prepared as above (SD synthetic culture medium, cell concentration: about 1.5 x 10 7 cells/ml) was used to collect the cells. The collected cells were then suspended in 10 ml of 100 mM potassium phosphate buffer solution (pH 7.0) and centrifuged (5000 x g, 10 min) to obtain pellets. Thus obtained pellets were resuspended in 2.0 ml of 100 mM potassium phosphate buffer solution (pH 7.0) and 1 ml of each of the solutions were poured into two cuvettes. After bubbling carbon monoxide to a sample cuvette, 5 to 10 mg of dithionite was added to both of the cuvettes, and stirred and then difference spectrum at 400-500 nm was measured to calculate the concentration of P450 present in the yeast. The amount of each kind of human P450 species or of an artificial fused enzyme in each kind of transformed yeast cells was at a level from about 10 5 to about 10 6 molecules/cell. Preparation of yeast S-9 Mix fraction, cytoplasmic fraction and microsomal fraction First, 3.8 liter of each kind of culture broth (SD synthetic culture medium, cell concentration: about 1.0 x 10 8 cells/ml) of yeast cells expressing human P450 molecular species and yeast NADPH-reductase simultaneously or an artificial fused enzyme comprising human P450 molecular species and yeast NADPH-reductase prepared as above was collected and the resultant cells were suspended in 400 ml of a buffer solution A (10 mM Tris-HCl (pH 7.5), 2 M sorbitol, 0.1 mM DTT, 0.2 mM EDTA), to which 160 mg of Zymolyase 100,000 (Zymolyase 100T) was added, and the obtained solution was incubated at 30°C for 60- min. Spheroplast obtained by centrifugation (5000 x g, 10 min) was suspended in 100 ml of the buffer solution A and then centrifuged (5000 x g, 10 min). Washing the spheroplast by repeating the same centrifugal operation once again, the spheroplast was finally suspended in 200 ml of a buffer solution (10 mM Tris-HCl (pH 7.5), 0.65 M sorbitol, 0.1 mM DTT), which was then subjected to ultrasonic pulverization (50 W, for 5 min). The cell free extracts were centrifuged (9000 x g, 20 min) and supernatants were recovered to obtain a yeast S-9 Mix fraction. Further, the fraction was centrifuged (125,000 x g, 70 min) to collect precipitates which were suspended again into 10 ml of 0.1 M potassium phosphate buffer solution (pH 7.4) to obtain a microsomal fraction. On the other hand, a cytoplasmic fraction was obtained by recovering the supernatants. Construction of yeast expression plasmid using GAPDH promoter and its expression in yeast Fig. 18 shows a method of constructing a yeast expression plasmid using a GAPDH promoter. A HindIII fragment (about 3.0 kb) obtained from pARRN (described in the Japanese Patent Laid-open Publication No. 2-211880) was inserted into a HindIII site of plasmid pUN, which was obtained by cleaving pUC19 with EcoRI, blunt-ending and ligation with an NotI linker to give pUR. On the other hand, after blunting an XhoI site of plasmid pAAH5 and inserting an XbaI linker, it was cleaved with restriction enzymes XbaI and SalI and the resultant fragment (about 2.2 kb) was inserted to XbaI and SalI sites of pUC19. The three fragments, namely, a fragment (about 2.2 kb) obtained by cleaving the resultant plasmid with XbaI and PstI, the XbaI-PstI fragment (about 1.3 kb) cut out from 2 µm DNA of Saccharomyces cerevisiae AH22, and a fragment obtained by cleaving pUR with PstI were ligated to give a plasmid pURL. Further, the pURL was cleaved with HindIII, blunted and ligated to remove the HindIII site. Then, a NotI fragment (about 1.6 kb) containing GAPDH promoter and terminator (obtained by the method as described in Agric. Biol. Chem., 51, 1641-1647 (1987) and J. Biol. Chem., 257, 16497-16502 (1992)) was ligated to the NotI site of pURL to give a plasmid pURLG. Human P450 2D6 cDNA obtained by the method used for the construction of p2D6 was inserted to a HindIII site of pURLG to obtain a yeast expression plasmid pG2D6R for simultaneous expression of human P450 2D6 and yeast NADPH-P450 reductase. When the plasmid was introduced by the method used in the preparation of transformed yeast cells as above to Saccharomyces cerevisiae AH22, production of human P450 2D6 was observed. Metabolism of 7-ethoxycoumarin using transformed yeast cells 7-Ethoxycoumarin was added to each 2 ml of the culture media of the transformed yeast cells expressing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase (SD synthetic culture medium, cell concentration: about 2.0 x 10 7 cells/ml) so that the final concentration of 7-ethoxycoumarin was 0.5 mM. After incubation at 30°C for 2 or 5 hours, supernatants were obtained by centrifugation (5000 x g, 10 min). To the supernatants 62.5 µl of 15% TCA (trichloroacetic acid) and 2 ml of chloroform were added and,- after well stirring, a chloroform layer was recovered by centrifugation (5000 x g, 10 min), to which 4 ml of 0.01 N NaOH containing 0.1 M NaCl was added and stirred sufficiently and then centrifuged (5000 x g, 10 min). After recovering the supernatants, fluorescence was measured for the supernatant fraction (ex. 366 nm, em 452 nm) to quantitatively measure the reaction product 7-hydroxycoumarin. As a result, O-deethylation activity for 7-ethoxycoumarin can be observed for all of 11 kinds of the yeast cells expressing the human P450 molecular species. P450 1A1 and P450 2B6 showed strong activity; and P450 1A2, P450 2E1, P450 2A6 and P450 2D6 showed good activity, while P450 2C8, P450 2C9, P450 3A4, P450 2C18 and P450 2C19 showed moderate activity. Metabolism of tolbutamide using transformed yeast cells In the same manner as above, tolbutamide was added to each of the culture solutions of the transformed yeast cells expressing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase so that the concentration of the compound was 1.0 mM. After incubation at 30°C for 15 hours, the culture supernatant was then obtained by centrifugation (5000 x g, 10 min). To the supernatant, 2 ml of dichloromethane was added. After sufficient stirring, the dichloromethane layer was recovered by centrifugation (5000 x g, 10 min), and the solvent was evaporated under reduced pressure. The resultant residue was dissolved in 100 µl of acetonitrile, and the solution was analyzed by HPLC under the following conditions. As a result, hydroxylated tolbutamide was detected in the solution of yeast cells expressing human P450 2C8, P450 2C9, P450 2C18 and P450 2C19. The human P450 2C9 showed high activity and 2C19 showed good activity. On the other hand, hydroxylated tolbutamide was not detected in the solution of yeast cells expressing other human P450 than described above. Conditions for HPLC Column: µBondapak C18 (manufactured by Waters Co.) Carrier: 10-70% acetonitrile-distilled water (linear concentration gradient for 20 min) Temperature: 50°C Detection: UV 230 nm Injection amount: 50 µl Metabolism of testosterone using transformed yeast cells In the same manner as above, testosterone was added to each of the culture solutions of the transformed yeast cells expressing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase so that the concentration of the compound was 0.05 mM. After incubation at 30°C for 15 hours, the supernatant was obtained by centrifugation (5000 x g, 10 min). Then 2 ml of dichloromethane was added. After sufficient stirring, the solution was centrifuged again (5000 x g, 10 min). The dichloromethane layer was recovered from the separated layer and the solvent was evaporated under reduced pressure. The resultant residue was dissolved in 100 µl of acetonitrile, and the solution was analyzed by HPLC under the following conditions. As a result, hydroxylated testosterone was detected for yeast cells expressing human P450 1A1, P450 2C8 and P450 3A4. On the other hand, hydroxylate testosterone was not detected for yeast cells expressing other human P450 than described above. Conditions for HPLC Column: µBondapak C18 (manufactured by Waters Co.) Carrier: 20-70% acetonitrile-distilled water (linear concentration gradient for 25 min) Temperature: 50°C Detection: UV 254 nm Injection amount: 50 µl Metabolism of chlorzoxazone using transformed yeast cells and microsomal fractions thereof Chlorzoxazone was added to each of the culture solutions of the transformed yeast cells expressing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase as above so that the concentration of the compound was 0.5 mM. After incubation at 30°C for 15 hours, the supernatant was obtained by centrifugation (5000 x g, 10 min). Then 2 ml of dichloromethane was added to the supernatant and vigorously stirred and centrifuged (5000 x g, 10 min). The dichloromethane layer was recovered from the separated layer, the solvent then evaporated under reduced pressure. The obtained residue was dissolved in 100 µl of acetonitrile, and the solution was analyzed by HPLC under the following conditions. NADPH and chlorzoxazone were added to a microsomal fraction of yeasts expressing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase prepared as above so that the concentrations of NADPDH and chlorzoxazone were 0.5 mM and 250 µM. Then the solutions were incubated at 37°C for 10 min. After that, trichloroacetic acid was added to the solutions so that the concentration of the trichloroacetic acid was about 10% (v/v). Then 2 ml of dichloromethane was added to the solution, and the solution was stirred vigorously and centrifuged (15,000 x g, 5 min). The dichloromethane layer was recovered, and the solvent was removed under reduced pressure. The obtained residue was dissolved in 100 µl of acetonitrile and the solution was subjected to analysis by HPLC under the same conditions as above. All of the yeast cells expressing one of the eleven human P450 molecular species gave hydroxylated chlorzoxazone. P450 2E1 showed high activity, and P450 1A1, P450 1A2, P450 2A6, P450 2D6 showed good activity, while P450 2C8, 2C9, 2B6, 2C18, 2C19 and 3A4 showed moderate activity. Ames test using yeast S-9 Mix fraction and microsomal fraction The Ames test method was in accordance with the customary method described, for example, in Mutat. Res., (1975) 31, 347. 2-Aminoanthrathene which is an arylamine type compound was used as a specimen compound. (1) Rat S-9 Mix supernatant fraction (obtained by homogenizing liver and then subjected to centrifugation (9000 x g, 10 min), manufactured by Kikkoman) containing each kind of rat P450 molecular species at the concentration of 1200 pmol per 1 sample and (2) Yeast S-9 Mix fraction obtained from each kind of yeast cells expressing human P450 or a microsomal fraction prepared from the yeast S-9 Mix fraction were used as a metabolic activation source in the Ames test. As a result, more than 1000 revertant colonies were detected for the compound at 1 µg/plate (90 mm dia.) only in the case of using the yeast S-9 Mix fraction obtained from the yeast cells expressing human P450 1A2 (Saccharomyces cerevisiae AH22/p1A2R) and yeast cells expressing human P450 2E1 (Saccharomyces cerevisiae AH22/p2E1R) and a microsomal fraction prepared from the yeast S-9 Mix fraction, while the amounts of the human P450 molecules of these fractions were only one five hundredth and one thirtieth of the human P450 molecules present in the Rat S-9 mixture. The human cytochrome P450 1A2 showed high activity, and human P450 2E1 showed only moderate activity. But the revertant colonies were not found for the human cytochromes P450 3A4, 2C8 and 2A6. Metabolism of acetanilide using transformed yeast cells Acetanilide was added to each of the culture solutions of the transformed yeast cells expressing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase, so that the concentration of the compound was 5 mM, and the solution was incubated at 30°C for 15 hours. Then the solution was centrifuged (5000 x g, 10 min) to give a supernatant. The obtained supernatant solution was subjected to the HPLC analysis under the following conditions. The hydroxylated acetanilide was found for all of the tested eleven human P450 molecular species. Among them, P450 1A2 and 2D6 showed high activity and P450 1A1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19 and 2E1 showed good activity, while 3A4 showed moderate activity. Conditions for HPLC Column: µBondapak C18 (manufactured by Waters Co.) Carrier: Methanol:water:acetic acid = 15:84:1 Temperature: 30°C Detection: UV 254 nm Injection amount: 50 µl Metabolism of coumarin using transformed yeast cells Coumarin was added to 6 ml of each of the culture solutions (SD synthetic culture medium, cell concentration of about 2.0 x 10 7 cells/ml) of the transformed yeast cells expressing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase prepared as above, so that the concentration of the compound was 5 mM, and the solution was incubated at 30°C for 2 or 5 hours. Then the solution was centrifuged (5000 x g, 10 min) to give a supernatant. 62.5 µl of 15% trichloroacetic acid and 2 ml of chloroform were added to the obtained supernatant solution, and the resultant solution was stirred well. The chloroform layer was recovered from the separated layer. Then 4 ml of sodium hydroxide solution containing 0.1 M NaCl was added to the solution and centrifuged again (5000 x g, 10 min). The supernatant fraction was recovered and subjected to fluorescence analysis (ex. 366 nm, em. 452 nm) to measure the 7-hydroxycoumarin formed. The hydroxylation activity was specifically found only for the yeast cells expressing the human P450 2A6, while other yeast cells showed no activity. Metabolism of debrisoquine using the microsomal fraction of transformed yeast whole cells NADPDH and [ 14 C]debrisoquine were added to each microsomal fraction solution containing (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase prepared as above, so that the concentration of the compound was 100 µM and that of NADPH is 6 mM, and the solution was incubated at 30°C for 30 minutes. Then perchlorate was added to the solution, so that the final concentration of the perchlorate was 10% (v/v). The solution was sufficiently stirred and centrifuged (15,000 x g, 15 min) to give the supernatant. The obtained supernatant was subjected to HPLC analysis according to the following conditions. Microsomal fractions of yeasts expressing P450 1A1 and 2D6 showed good activity for the hydroxylation of the debrisoquine, while those of yeast cells expressing other human P450 molecular species showed no activity. Conditions for HPLC Column: COSMOSIL 5C18 (manufactured by Nakarai Tesq Co.) Carrier: A(acetonitrile)/B(20mM Sodium Perchlorate, pH = 2.5) Time (minute) A/B 0-15 9/91 15-30 9/91-25/75 (linear gradient) 30-32 100/0 32-42 9/91 Temperature: room temperature Detector: RI 14 C Injection amount: 100 µl Metabolism of S-mephenytoin using the microsomal fraction of transformed yeast cells NADPH and [ 14 C]S-mephenytoin were added to each microsomal fraction solution of (i) human cytochrome P450 molecular species and yeast NADPH-P450 reductase; or (ii) an artificial fused enzyme comprising human cytochrome P450 molecular species and yeast NADPH-P450 reductase prepared as above, so that the concentration of the compound was 25 µM and that of NADPH was 3 mM, and the solution was incubated at 30°C for 30 minutes. Then the solution was diluted with an equal volume of methanol, sufficiently stirred and centrifuged (15,000 x g, 5 min) to give the supernatant. The obtained supernatant was subjected to HPLC analysis according to the following conditions. Microsomal fractions of yeasts expressing P450 2C19 showed good activity for the hydroxylation of the S-mephenytoin, while those of yeast cells expressing other human P450 molecular species showed no activity. Conditions for HPLC Column: COSMOSIL 5C18 (manufactured by Nakarai Tesq Co.) Carrier: A:(Methanol)/(20 mM potassium phosphate buffer, pH = 7.0) = 40/60 B:Methanol Time (minute) A/B 0-18 100/0 18-20 0/100 20-35 100/0 Temperature: room temperature Detector: RI 14 C Specimen amount: 100 µl Metabolism of chlorzoxazone using a mixture of microsomal fractions of transformed yeast cells Microsomal fractions of yeast expressing cytochrome P450 prepared as above were mixed in the following molar ratios, and the hydroxylation activities of the mixed solutions were measured using chlorzoxazone. P450 System A System B 3A4 35% 33% 2C9 25% 5.8% 2C8 5.8% 2C18 5.8% 2C19 5.8% 1A2 23% 19% 2E1 17% 15% 1A1 2.4% 2A6 3.0% 2B6 2.4% 2D6 2.4% The substrate, [ 14 C]chlorzoxazone and NADPH were added to the mixed yeast microsomal fractions, so that the concentrations of the compound and NADPH were 382 µM and 3 mM. The solutions were incubated at 37°C for 30 min, and then 1 ml of dichloromethane was added thereto to stop the reaction. After stirring, dichloromethane layer was recovered by centrifugation (10,000 x g, 5 min). Then the solvent was evaporated by the stream of nitrogen gas. The obtained residue was dissolved in 54 µl of acetonitrile and 146 µl of water, the solution was subjected to HPLC analysis under the following conditions. Conditions for HPLC Column: COSMOSIL 5C18 (manufactured by Nakarai Tesq Co.) Carrier: A(Acetonitrile/Water = 27/73) B(Acetonitrile) Time (minute) A/B 0-15 100/0 15-17 0/100 17-25 100/0 Temperature: room temperature Detector: RI 14 C Injection amount: 100 µl The metabolites of chlorzoxazone observed by each of the mixed systems A and B were similar to those metabolites which Guengerich reported based on their experimental results by using human liver microsomal fractions (Guengerich, F.P., Chem. Toxicil., Vol.3, pp.566-573, 1990). Furthermore, the metabolic turnover numbers were calculated for the human liver microsomal fraction (by Guengerich) and for the present yeast microsomal fractions. The turnover numbers were calculated to be 1.8 and 1.6 in the mixed systems A and B, respectively. The turnover V for the human liver microsomal fraction was calculated using V max , K m and substrate concentration [S] described in the literature according to the following manner. The results are shown in Table 2. The values somewhat varied due to the difference of individuals, the lowest value being 1.0 and the highest value being 5.9. The values of V for the mixed systems B and A fell within this range, both of which were the same level. It was confirmed that the four kinds of molecular species in system A can well reproduce the metabolic system in human liver in vitro. The turnover V for human cytochrome P450 at an optional substrate concentration can be calculated by substituting V max and K m described in the literature and substrate concentration [S] of the present example into the Michaelis-Menten's equation: V=(V max * [S])/(K m + [S]) Liver sample Metabolic turnover V [product nmol/nmol P450/min] #1001 5.9 KDL 14 2.2 KDL 21 1.7 KDL 23 3.0 KDL 27 5.0 H 10 1.1 H 11 1.0 H 12 4.2 H 13 3.3 H 14 2.1 H 15 4.3 H 16 4.0 H 17 3.6 H 18 3.4 Designations of the human liver sample were those used by Guengerich. Metabolism of debrisoquine using mixture of microsomal fractions of transformed yeast cells Microsomal fractions of yeasts expressing human cytochrome P450 were mixed, and the hydroxylation activity of the mixed fraction was measured using debrisoquine. The mixing molar ratio of the human cytochrome P450 molecular species were as follows: P450 Molar ratio 3A4 33% 2C9 5.8% 2C8 5.8% 2C18 5.8% 2C19 5.8% 1A2 19% 2E1 15% 1A1 2.4% 2B6 2.4% 2D6 2.4% The substrate debrisoquine and NADPH were added to the mixed microsomal fraction solutions, so that the concentrations were 100 µM for the NADPH and 6 mM for the compound. After the mixture was incubated at 37°C for 30 min, 50 µl of 60% perchlorate was added to the solution to stop the reaction. The concentration of the perchlorate was finally 12.5% (v/v). After vigorous stirring, the mixture was centrifuged (15,000 x g, 5 min) to recover the supernatant, which was subjected to HPLC analysis under the same conditions used for analyzing the metabolites of debrisoquine. The metabolites well coincided with the metabolites which Kronbach reported based on the experiments to metabolize the debrisoquine using the human liver microsome (Methods in Enzymology, Vol.206, pp.509-517, 1991). Metabolism of S-mephenytoin using mixture of microsomal fractions of transformed yeast cells Microsomal fractions of yeasts expressing various human cytochrome P450 species prepared as above were mixed, and the hydroxylation activity of the mixed fraction was measured for S-mephenytoin. The mixing ratio of the human cytochrome P450 molecular species was the same as that of the mixing system B as described above. The substrate, [ 14 C]S-mephenytoin and NADPH were added to the mixed microsomal fraction solutions, so that the concentrations were 28 µM for the NADPH and 6 mM for the compound. After the mixture was incubated at 37°C for 30 min, 250 µl of methanol was added to the solution to stop the reaction. After vigorous stirring, the mixture was centrifuged (15,000 x g, 5 min) to recover the supernatant, which was subjected to HPLC analysis under the same conditions used for the hydroxylation of S-mephenytoin using microsomal fraction. The metabolites obtained well coincided with the metabolites which Goldstein reported based on the experiments to metabolize the S-mephenytoin using the human liver microsome (Biochemistry, Vol.33, pp.1743-1752, 1994). SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Sumitomo Chemical Company, Limited (B) STREET: 5-33, Kitahama 4-chome, Chuo-ku, (C) CITY: Osaka-shi, Osaka-fu (E) COUNTRY: Japan (F) POSTAL CODE (ZIP): none (ii) TITLE OF INVENTION: METHOD FOR SAFETY EVALUATION OF CHEMICAL COMPOUND USING RECOMBINANT YEAST EXPRESSING HUMAN CYTOCHROME P450 (iii) NUMBER OF SEQUENCES: 61 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO) (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: JP 201120/1993 (B) FILING DATE: 20-JUL-1993 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: JP 180246/1993 (B) FILING DATE: 21-JUL-1993 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: JP 208279/1993 (B) FILING DATE: 30-JUL-1993 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1551 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1548 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 516 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1470 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 490 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1482 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1479 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 493 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1512 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1509 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 503 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1539 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1536 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 512 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1539 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1536 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 512 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1539 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1536 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 512 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1485 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1482 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 494 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1485 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1482 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 494 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1476 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1473 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 491 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1470 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 490 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1470 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 490 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1470 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 490 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1470 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 490 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1470 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 490 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1494 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1491 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 497 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1494 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1491 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 497 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1494 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1491 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 497 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1494 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1491 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 497 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 56 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55: (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 64 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 55 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57: (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58: (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 52 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

Claims: A method for evaluation of the safety of a chemical compound, which comprises the steps of: (a) reacting a chemical compound with recombinant yeast cells producing human cytochrome P450 molecular species P450 1A2, P450 2C9, P450 2E1 and P450 3A4 together with a yeast NADPH-P450 reductase, which may be in the form of a fused enzyme with each of said human cytochrome P450 molecular species, or with the cell free extracts of the yeast cells; and (b) analyzing the resulting metabolite to determine the safety of the compound. The method according to claim 1, wherein the recombinant yeast cells are yeast cells transformed with plasmids having a gene coding for human cytochrome P450 1A2, P450 2C9, P450 2E1 or P450 3A4 together with a gene coding for yeast NADPH-P450 reductase. The method according to claim 1 or 2, wherein the recombinant yeast cells are yeast cells transformed with plasmids each of which has a fused gene comprising a gene coding for the human cytochrome P450 molecule on the 5'-terminal and a gene coding for the yeast NADPH-P450 reductase on 3'-terminal. The method according to any one of claims 1 to 3, wherein the analyzing of the metabolite is carried out by the Ames Test. The method according to claim 4, wherein the test is carried out using His - Salmonella or Trp - Escherichia coli. The method according to any one of claims 1 to 5, wherein the recombinant yeast cells further produce at least one additional human cytochrome P450 molecular species selected from a group of human cytochrome P450 2A6, P450 2C19 and P450 2D6. The method according to any one of claims 1 to 6, wherein the recombinant yeast cells further produce at least one additional human cytochrome P450 molecular species selected from a group of human cytochrome P450 1A1, P450 2B6, P450 2C8 and P450 2C18. An artificial fused enzyme, which comprises human cytochrome P450 3A4 and yeast NADPH-P450 reductase. A yeast expression plasmid having a fused gene comprising a gene coding for human P450 3A4 and a gene coding for the yeast NADPH-P450 reductase. A method of determining in vitro the human metabolite of a chemical compound, which comprises the steps of: (a) reacting a chemical compound with recombinant yeast cells producing human cytochrome P450 molecular species P450 1A2, P450 2C9, P450 2E1 and P450 3A4 together with a yeast NADPH-P450 reductase, which may be in the form of a fused enzyme with each of said human cytochrome P450 molecular species, or with the cell free extracts of the yeast cells; and (b) identifying the resulting metabolite.

Inventors: HAYASHI KOJI, KANEKO HIDEO, KOMAI KOICHIRO, NAKATSUKA IWAO, SAKAKI TOSHIYUKI, YABUSAKI YOSHIYASU, HAYASHI, KOJI, KANEKO, HIDEO, KOMAI, KOICHIRO, NAKATSUKA, IWAO, SAKAKI, TOSHIYUKI, YABUSAKI, YOSHIYASU
Applicants: SUMITOMO CHEMICAL CO, SUMITOMO CHEMICAL COMPANY, LIMITED
Application year: 1994
Main classification: C12Q1
IPC codes: C12Q1, C12N9, C12N15